Tag Archives: dengue

Floral-scented fungus (engineered by scientists) lures mosquitoes to their doom

Climate warming means more mosquitoes traveling north bring malaria and other diseases with them.Scientists at the University of Maryland have developed a new means of dealing with the coming influx. From an October 27, 2025 news item on ScienceDaily,

To combat mosquito-borne illnesses that claim hundreds of thousands of lives each year, scientists have enlisted an unexpected partner: a fungus that gives off a floral scent.

By exploiting mosquitoes’ attraction to flowers, an international team of researchers engineered a new strain of Metarhizium fungus that releases a sweet aroma similar to real blooms. The modified fungus draws in the insects and infects them, ultimately killing them.

An October 24, 2025 University of Maryland news release (also on EurekAlert), which originated the slightly edited news item, describe the work in more detail, Note: A link has been removed,

Inspired by certain fungi that the team found emit a sweet-smelling chemical called longifolene to draw insect prey, they created what’s essentially a deadly perfume for mosquitoes—offering new hope against malaria, dengue and other fatal diseases that traditional methods, like chemical pesticides, can no longer control. The researchers documented their invention and its ability to control mosquitoes in a new paper published in the journal Nature Microbiology on October 24, 2025. 

“Mosquitoes need flowers because they provide nectar, a crucial source of food for them, and they are drawn to flowers through their scents,” explained paper co-author Raymond St. Leger, a Distinguished University Professor of Entomology at the University of Maryland. “After observing that some types of fungi could trick mosquitoes into thinking they were flowers, we realized we could turbo-charge the attraction by engineering fungi to produce more longifolene, a sweet-smelling compound that’s already very common in nature. Before this study, longifolene wasn’t known to attract mosquitoes. We’re letting nature give us a hint to tell us what works against mosquitoes.” 

St. Leger noted that the floral-scented fungus is an easy-to-use control method against mosquitoes, requiring little to no training or specialized knowledge. As soon as the fungus spores are placed in a container, either indoors or outdoors, longifolene is instantly and gradually released, maintaining effectiveness for months. Once mosquitoes encounter the fungus, they become infected and die within days. In lab tests, the fungus killed 90 to 100% of mosquitoes—even when placed in a large room with competing scents from humans and real flowers. Although the fragrant fungus is deadly to mosquitoes, it is harmless to humans.

“The fungus is completely harmless to humans as longifolene is already commonly used in perfumes and has a long safety record,” St. Leger said. “This makes it much safer than many chemical pesticides. We’ve also designed the fungus and its containers to target mosquitoes specifically rather than any other insects and longifolene breaks down naturally in the environment.” 

In addition, unlike chemical alternatives that mosquitoes have gradually become resistant to, this biological approach may be nearly impossible for mosquitoes to outsmart or avoid. 

“If mosquitoes evolve to avoid longifolene, that could mean they’ll stop responding to flowers,” St. Leger explained. “But they need flowers as a food source to survive, so it would be very interesting to see how they could possibly avoid the fungus yet still be attracted to the flowers they need. It’ll be very difficult for them to overcome that hurdle, and we have the option of engineering the fungus to produce additional floral odors if they evolve to specifically avoid longifolene.”

What also makes this new fungal technology particularly promising is how practical and affordable it is to produce. Other forms of Metarhizium are already commonly cultivated around the world on cheap materials like chicken droppings, rice husks and wheat scraps that are readily available after harvest. The affordability and simplicity of the fungus could be key to reducing mosquito disease-related deaths in many parts of the world, especially in poorer countries in the global south. 

Finding effective new weapons against mosquitoes could be more important than ever. St. Leger warns that in the future, mosquito-borne diseases currently limited to tropical regions could threaten new targets, including the United States. With rising global temperatures and the growing unpredictability of weather, disease-carrying mosquitoes have begun to spread to new areas beyond their usual habitats.

“Mosquitoes love many of the ways we are changing our world,” St. Leger said. “Right now, we’re hoping to use these approaches in Africa, Asia and South America. But one day, we may need them for ourselves.”

St. Leger and his collaborators are currently working on larger-scale outdoor trials of their mosquito control method to submit for regulatory approval. 

“It’s not as if you’re going to necessarily find a silver bullet to control mosquitoes everywhere, but we’re trying to develop a very diverse and flexible set of tools that people in different parts of the world can use and choose from,” St. Leger said. “Different people will find different approaches work best for their particular situation and the particular mosquitoes they’re dealing with. In the end, our goal is to give people as many options as possible to save lives.”

Here’s a link to and a citation for the paper,

Engineered Metarhizium fungi produce longifolene to attract and kill mosquitoes by Dan Tang, Jiani Chen, Yubo Zhang, Xingyuan Tang, Xinmiao Wang, Chaonan Yu, Xianxian Cheng, Junwei Zhang, Wenqi Shi, Qing Zhen, Shuxing Liu, Yizhou Huang, Jiali Ning, Guoding Zhu, Meichun Zhang, Juping Hu, Etienne Bilgo, Abdoulaye Diabate, Sheng-Hua Ying, Jun Cao, Raymond J. St. Leger, Jianhua Huang & Weiguo Fang. Nature Microbiology volume 10, pages 3075–3093 (2025) Published: 24 October 2025 Version of record: 24 October 2025 Issue date: December 2025 DOI: https://doi.org/10.1038/s41564-025-02155-9

This paper is behind a paywall.

Dengue fever and NanoViricides, Inc.

Since 1970, dengue has grown to be a major health problem according to the World Health Organization Fact Sheet no. 117 (November 2012, *ETA August 9, 2023: There is a March 17, 2023 fact sheet update which is focused on more contemporary events and statistics*) and it’s one NanoViricides, Inc. hopes to tackle with its current European Medicines Agency (EMA) drug application. From the July 2, 2013 news item on Azonano,

NanoViricides, Inc. (the “Company”) announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency (EMA) for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

EMA requires a notification of intent to file at least 60 days prior to the actual filing, unlike the US FDA. The actual application will need to be translated into 27 different languages prior to submission.

… The Company has recently filed an Orphan Drug Designation application for DengueCide to the US FDA.

The July 1, 2013 NanoViricides news release, which originated the news item, goes on to explain (a direct link to the news release is not possible but you can find it on the company’s home page),

Dengue fever, a very old disease, has reemerged in the past 20 years with an expanded geographic distribution of both the viruses and the mosquito vectors, increased epidemic activity, the development of hyper-endemicity (the co-circulation of multiple serotypes), and the emergence of dengue hemorrhagic fever in new geographic regions. In 2013, this mosquito-borne disease is one of the most important tropical infectious diseases globally, with an estimated 400 million cases of dengue fever, over one million cases of dengue hemorrhagic fever, and 50,000-100,000 deaths annually. Dengue virus occurs in four primary serotypes. Although the disease is endemic in many tropical parts of the world, it is considered an orphan disease in the USA and Europe. (From Clinical Microbiology Reviews).

The news release also describes the proposed DengueCide treatment’s effectiveness in animal trials,

DengueCide is a nanoviricide® that has shown very high effectiveness in an animal model of dengue virus infection. These animal studies were conducted in the laboratory of Dr. Eva Harris, Professor of Public Health and Infectious Diseases at the University of California, Berkeley. Professor Harris has developed a mouse model simulating antibody-dependent-enhancement (ADE) of dengue infection using a special laboratory mouse strain called AG129. ADE in humans is thought to to lead to dengue hemorrhagic fever, and is associated with a high fatality rate. In this model, infection with a dengue virus, when the mice are left untreated, is 100% fatal. In contrast, in the same study, animals treated with NanoViricides’ DengueCide achieved an unprecedented 50% survival rate.

There is currently neither an effective drug treatment nor a vaccine for dengue virus infection. Tremendous efforts have been made for dengue vaccine development but, to date, no vaccine candidate has succeeded in clinical trials towards approval.

In an attempt to give their DengueCide application more heft, the news release provides a description of the company’s work with anti-influenza drugs,

NanoViricides is developing broad-spectrum anti-influenza drugs as part of its rich drug pipeline. The Company believes that its FluCide™ drug candidates will be effective against most if not all influenza viruses, including the H7N9 bird flu, H3N2 or H1N1 epidemic viruses, H5N1 bird flu, seasonal influenzas, as well as novel influenza viruses. This is because FluCide is based on the Company’s biomimetic technology, mimicking the natural sialic acid receptors for the influenza virus on the surface of a nanoviricide® polymeric micelle. It is important to note that all influenza viruses bind to the sialic acid receptors, even if they rapidly mutate. The FluCide drug candidates have already shown strong effectiveness against H1N1 and H3N2 influenza viruses in highly lethal animal models. The injectable FluCide drug candidates have shown 1,000X greater viral load reduction as compared to oseltamivir (Tamiflu®), the current standard of care, in a highly lethal influenza infection animal model. The Company believes that these animal model results should translate readily into humans.

NanoViricides has also developed an oral drug candidate against influenza. This oral version is also dramatically more effective than TamiFlu in the animals given a lethal influenza virus infection. This oral FluCide may be the very first nanomedicine that is effective when taken by mouth.

I hope they are successful with this new dengue drug. Oddly, the news release seemed to understate the scope of the problem. Here’s more from the WHO (World Health Organization) fact sheet no. 117,

The incidence of dengue has grown dramatically around the world in recent decades. Over 2.5 billion people – over 40% of the world’s population – are now at risk from dengue. WHO currently estimates there may be 50–100 million dengue infections worldwide every year.

Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific. The American, South-east Asia and the Western Pacific regions are the most seriously affected.

Cases across the Americas, South-east Asia and Western Pacific have exceeded 1.2 million cases in 2008 and over 2.3 million in 2010 (based on official data submitted by Member States). Recently the number of reported cases has continued to increase. In 2010, 1.6 million cases of dengue were reported in the Americas alone, of which 49 000 cases were severe dengue.

Not only is the number of cases increasing as the disease spreads to new areas, but explosive outbreaks are occurring. The threat of a possible outbreak of dengue fever now exists in Europe and local transmission of dengue was reported for the first time in France and Croatia in 2010 and imported cases were detected in three other European countries. A recent (2012) outbreak of dengue on Madeira islands of Portugal has resulted in over 1800 cases and imported cases were detected in five other countries in Europe apart from mainland Portugal.

An estimated 500 000 people with severe dengue require hospitalization each year, a large proportion of whom are children. About 2.5% of those affected die.